Aleksandra Rachitskaya, MD
Retina Specialist · Cleveland, OHNPI 1487802757
Payments from drug & device makers
Across 315 payments — averaging $6774.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$933K
- Genentech, Inc.$742K
- Novartis$187K
- Alcon$53K
- Boehringer Ingelheim International GmbH$35K
- Cortigent Inc$27K
- plus $157K from 15 others
Across 16 payments — averaging $971.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$16K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 39 | $933,417 |
| Genentech, Inc. | 81 | $741,999 |
| Novartis | 17 | $186,548 |
| Alcon | 43 | $53,015 |
| Boehringer Ingelheim International GmbH | 8 | $34,939 |
| Cortigent Inc | 3 | $27,272 |
| Regeneron Healthcare Solutions, Inc. | 16 | $22,146 |
| Alcon Research LLC | 11 | $20,426 |
| Regeneron | 13 | $17,865 |
| Astellas Pharma US Inc | 8 | $15,909 |
| F. Hoffmann-la Roche AG | 6 | $15,588 |
| Ocular Therapeutix, Inc. | 12 | $15,575 |
| Carl Zeiss Meditec, Inc. | 11 | $13,670 |
| Genentech USA, Inc. | 10 | $13,156 |
| AbbVie(2 entities) | 19 | $10,777 |
| Eyepoint US, Inc. | 7 | $3,784 |
| Roche Products Limited | 3 | $3,197 |
| Samsara Vision | 2 | $2,424 |
| Alimera Sciences, Inc. | 4 | $1,304 |
| Bausch & Lomb Americas Inc. | 1 | $825 |
| Celltrion USA Inc. | 1 | $16 |
How this compares
$2,133,850 in reported general payments places this provider in the 95th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Cleveland
- Sumit SharmaCleveland$1.5M
- Katherine TalcottCleveland$795K
- Phoebe LinCleveland$323K
- Suber HuangCleveland$128K
- Ananth SastryCleveland$44K
- Warren SobolCleveland$5K
- Mark SeralyCleveland$3K
- Abhishek NaiduCleveland$3K
- Mary-Grace ReevesCleveland$2K
- Matthew OhrColumbus$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.